- Home
- OFS vs MREO Comparison
OFS vs MREO Comparison
Compare OFS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | MREO |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United Kingdom |
| Employees | 47 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.2M | 52.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | OFS | MREO |
|---|---|---|
| Price | $4.02 | $0.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 130.6K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 16.67% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $6,000.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $0.20 |
| 52 Week High | $9.31 | $2.94 |
Technical Indicators
Market Signals| Indicator | OFS | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 39.41 |
| Support Level | $2.72 | $0.32 |
| Resistance Level | $4.44 | $0.42 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 92.20 | 30.56 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).